Cepheid Schedules 2012 First Quarter Financial Results Announcement and Webcast

  //science-technology.news-articles.net/content/2 .. -financial-results-announcement-and-webcast.html
  Published in Science and Technology on Thursday, April 5th 2012 at 13:27 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

Cepheid Schedules 2012 First Quarter Financial Results Announcement and Webcast -- SUNNYVALE, Calif., April 5, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about CPHD

SUNNYVALE, Calif., April 5, 2012 /PRNewswire/ -- Cepheid (Nasdaq: [ CPHD ]) today announced that it will report financial results for its 2012 first quarter on Thursday, April 19, 2012, after the close of the market.

The Company will host a management presentation at 2 p.m. Pacific Time on Thursday, April 19, 2012, to discuss the results.  To access the live webcast, please visit Cepheid's website at [ www.cepheid.com/investors ] at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software.  A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

Interested participants and investors may also listen to the live teleconference call by dialing (800) 920-8624 or (617) 597-5430, and entering participant code 71854034.  A replay will be available for seven days beginning at 4 p.m. Pacific Time.  Access numbers for this replay are (888) 286-8010 or (617) 801-6888, with passcode 29985463.

About Cepheid

Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.  By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.  Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit [ http://www.cepheid.com ].

SOURCE Cepheid

RELATED LINKS
[ http://www.cepheid.com ]